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Abstract
Liver disease represents an increasing cause of global morbidity and mortality. Currently, liver
transplant is the only treatment curative for end-stage liver disease. Donor organs cannot meet the
demand and therefore scalable treatments and new disease models are required to improve clinical
intervention. Pluripotent stem cells represent a renewable source of human tissue. Recent advances
in three-dimensional cell culture have provided the field with more complex systems that better
mimic liver physiology and function. Despite these improvements, current cell-based models are
variable in performance and expensive to manufacture at scale. This is due, in part, to the use of
poorly defined or cross-species materials within the process, severely affecting technology
translation. To address this issue, we have developed an automated and economical platform to
produce liver tissue at scale for modelling disease and small molecule screening. Stem cell derived
liver spheres were formed by combining hepatic progenitors with endothelial cells and stellate cells,
in the ratios found within the liver. The resulting tissue permitted the study of human liver biology
‘in the dish‘ and could be scaled for screening. In summary, we have developed an automated
differentiation system that permits reliable self-assembly of human liver tissue for biomedical
application. Going forward we believe that this technology will not only serve as an in vitro
resource, and may have an important role to play in supporting failing liver function in humans.
1. Introduction
The liver is the largest internal organ performing
hundreds of different functions [1]. Parenchymal
cells of the liver (hepatocytes) make up approx-
imately 70–80% of the liver’s mass and perform
most of the metabolic functions. Hepatocytes are
highly polarised epithelial cells and their func-
tion is supported by the non-parenchymal cells
that reside in the liver [2]. Their basolateral sur-
face is in direct contact with sinusoidal endothelial
cells, facilitating efficient transfer of substrates
between the blood and the liver. The tight junc-
tions between hepatocytes form the apical membrane
that collects and transports bile [3]. The organised
structure of the liver is key to the organ’s ability to
perform a myriad of metabolic functions and regen-
erate when necessary. During liver damage, the loss of
this structure, and intimate cell interactions becomes
evident, and if uncorrected leads to the development
of disease.
Currently, liver disease is a global health
issue. Although the liver is a highly regenerat-
ive organ, the exposure to serious or repeated
injury severely impairs this process. This can
lead to reduced organ function and altered
physiology, often requiring clinical intervention.
While end-stage liver disease can be successfully
© 2020 The Author(s). Published by IOP Publishing Ltd
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treated by organ transplantation, it is an invasive
surgical procedure, which is limited by organ
donation [4]. Therefore, development of renew-
able sources of human liver tissue to treat disease are
eagerly awaited [4]. In addition to organ and tissue
transplantation, human liver tissue has an import-
ant role to play in disease modelling and improv-
ing the efficiency of the drug development process
[5–8].
To date, the field relies on different types of cell-
based systems to model human liver biology. Primary
human hepatocytes are considered as the gold stand-
ard model, however their isolation from diseased tis-
sue, poor scalability and rapid loss of phenotype lim-
its their routine use for modelling studies in vitro
[9]. Therefore, cancer derived cell lines have been
developed and are widely used to study human liver
biology ‘in the dish’, due to their abundance and cost-
effective scale-up [10]. Despite their advantages, cell
lines offer limited biological relevance when com-
pared to primary human tissue. As a result, research-
ers have turned their attention to renewable cell-
based systems. In particular, pluripotent stem cell
technology has been proposed as a suitable altern-
ative to overcome limitations associated with organ
scarcity, loss of cell phenotype and routine use of
cancer cell lines [11]. A number of efficient hepato-
cyte differentiation procedures frompluripotent stem
cells have been developed (for a literature review see
[12]). Thosemodels have been used to study different
aspects of liver disease, such as metabolic disorders
[13, 14], non-alcoholic fatty liver disease [15, 16], and
drug induced liver injury (DILI) [17, 18]. Although
proof of concept has been established, further modi-
fications to thosemodels are required to improve data
quality and extrapolation toward human physiology
[19].
Most liver models used for large-scale exper-
imentation, are two-dimensional (2D) in nature.
These simplistic environments are useful, but also
lead to non-physiological alterations in many cellu-
lar processes, including cytoskeleton formation and
extracellular matrix protein production [12]. These
alterations have significant impact on cell phenotype
and model accuracy [20]. For example, in the case of
the liver and drug exposure, changes driven by 2D cul-
ture alter hepatocyte polarity and therefore exposure
to drugs [21]. Although 2D models do not accurately
capture human organ function, recent experimenta-
tion demonstrates that significant progress has been
made extrapolating simple in vitro model data to in
vivo exposure levels in humans [22].
To improve tissue performance and phenotype,
researchers have developed 3D models, which better
capture aspects of organ development and structure.
In the context of the liver, this approach has been
shown to substantially improve cell phenotype and
stability in vitro [23, 24]. The pioneering studies by
Takebe et al demonstrated that primary endothelial
cells, mesenchymal stem cells and stem cell derived
hepatocytes could be used to generate 3D liver like
tissue that performed in vitro and in vivo [25]. More
recently, Takebe et al built functional liver tissue
wholly from human iPSC derivatives, representing a
significant advance for the field [26], although the
system has not been used for large-scale production
as of yet. Alternative approaches to generate func-
tional liver tissue and to better understand multi-
lineage communication have also been developed by
a number of other groups using self and template-
based cell assembly (for a literature review see [12]).
Whilst significant advances have been made, key
challenges remain to manufacture human liver tis-
sue. Those include intra- and inter-experimental
consistency, and cost effective production at scale
[12, 27].
While it is clear that human pluripotent stem
cells have revolutionary potential for modern medi-
cine [28]. Most procedures published to date rely on
undefined and/or xenobiotic materials to expand,
differentiate and engineer units of human tissue.
The incorporation of these types of materials into
the manufacturing process are known to elicit
uncontrolled effects that can lead to variable cell
performance and therefore batch-to-batch variation.
This was recently highlighted as a key limitation to
using current organoid systems to study human liver
biology [27]. Although these limitations are not huge
hurdles for small scale lab-based research, they serve
as significant challenges for technology scale-up, pro-
cess automation and technology translation.
Therefore, the objectives of our study were to
build a fully defined stem cell-based tissue engin-
eering platform, that was capable of automation,
was transferable between users and could be used to
model human liver disease. Our hypothesis was that
the combination of defined cellular differentiation,
cell self-assembly and engineering processes were
essential to achieve this goal. We report the develop-
ment of a robust and automated tissue-engineering
platform to produce 3D human liver tissue at scale
and use this to model human disease and perform
small molecule screening.
2. Material andmethods
2.1. Cell culture and differentiation
2.1.1. Maintenance of human PSCs
Human pluripotent stem cells (hPSC) lines, includ-
ing two embryonic stem cell lines (H9 and Man12)
and an iPSC line (P106) were cultured on Laminin
521 (Biolamina) coated plates in serum-free mTeSR1
™ (STEMCELL Technologies) in a humidified 37 ◦C,
5%CO2 incubator as previously described (Cameron
et al 2015). Cells were routinely passaged usingGentle
Cell Dissociation Reagent (STEMCELL Technolo-
gies) and replated as small clumps of cells at a dilu-
tion of 1:6–1:10. The cell lines were propagated in
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antibiotic freemedium and tested regularly formyco-
plasma infection.
2.1.2. Hepatic differentiation
For hepatic differentiation, hPSCs were dissociated
using Gentle Cell Dissociation Reagent (STEMCELL
technologies) and plated onto pre-coated wells with
Laminin 521 (BioLamina) in mTeSR1™ supplemen-
ted with 10 µM Y-27632 (Biotech) at a density
of 40 000 cells cm−2. Differentiation was initiated
24 h post seeding when cell confluency reached 40%
by replacing stem cell medium with endoderm dif-
ferentiation medium [RPMI 1640 containing 1×
B27 (Life Technologies), 100 ng ml−1 Activin A
(Biotech) and 50 ng ml−1 Wnat3a (Biotech)]. The
medium was changed every 24 h for 3 d. On day
4, endoderm differentiation medium was replaced
with hepatic progenitor differentiation medium, and
this was renewed every second day for a further
5 d. The medium consisted of knockout (KO)-
DMEM (Life Technologies), Serum replacement (Life
Technologies), 0.5% Glutamax (Life Technologies),
1% non-essential amino acids (Life Technologies),
0.2% β-mercaptoethanol (Life Technologies), and
1% DMSO (Sigma). On day 9, differentiating cells
were cultured in the hepatocyte maturation medium
which comprised of Hepato-ZYME (Life Technolo-
gies) containing 1% Glutamax (Life Technologies),
supplemented with 10 ng ml−1 hepatocyte growth
factor (PeproTech) and 20 ng ml−1 oncostatin m
(PeproTech) as described previously [28].
2.1.3. Endothelial cell differentiation
Endothelial differentiation was performed using an
adapted a protocol previously described [29]. Briefly,
hPSCs were dissociated using Gentle Cell Dissoci-
ation Reagent (STEMCELL technologies) and plated
onto pre-coated wells with Laminin 521 in mTeSR1™
supplemented with 10 µM Y-27632 (Biotech) at a
density of 25 000 cells cm−2. After 24 h the media
was replaced with mesoderm priming medium, con-
sisting of N2B27medium (1:1mixture of DMEM:F12
and CTS Neurobasal media) supplemented with
Glutamax N2 CTS, B27 CTS (Life Technologies),
10 µM CHIR99021 (Tocris) and 25 ng ml−1 BMP4
(Biotech). After three days, the priming medium was
replaced by endothelial induction medium consist-
ing of StemPro-34 SFM medium (Life Technologies)
supplemented with 200 ng ml−1 vascular endothelial
growth factor (VEGF) (Biotech) and 2 µM for-
skolin (Sigma-Aldrich). The induction medium was
renewed after 24 h.
2.1.4. Hepatic stellate cell differentiation
Hepatic stellate cell differentiation was achieved
using an adapted protocol previously described [30].
Briefly, hPSC were dissociated using Gentle Cell
Dissociation Reagent (STEMCELL technologies) and
plated onto pre-coated wells with Laminin 521 in
mTeSR1 ™ supplemented with 10 µM Y-27632
(Biotech) at a density of 75 000 cells cm−2. Differenti-
ationwas initiated 24 h post seeding by replacing stem
cell medium with hepatic stellate cell (HSC) differ-
entiation medium [57% DMEM low glucose (Ther-
moFisher), 40% MCDB-201-water (Sigma), 0.25×
linoleic acid-bovine serum albumin (Sigma), 0.25×
insulin-transferrin-selenium (Sigma), 1% penicil-
lin streptomycin (ThermoFisher Scientific), 10−4 M
L-ascorbic acid (Sigma), 2.5 µM dexamethasone
(Sigma) and 50 µM 2-mercaptoethanol (Life Tech-
nologies)]. Medium was changed every 48 h. Growth
factors (Biotech) were added as follows: 20 ng ml−1
BMP4 from days 0 to 4, 20 ng ml−1 FGF1 and
20 ng ml−1 FGF3 from days 4 to 8, 50 µM ret-
inol (Sigma) and 100 µM palmitic acid (Sigma) were
added from days 6 to 12.
2.1.5. Formation and maintenance of self-aggregated
liver spheres
Agarose microplates were manufactured in 256-well
format using the 3D Petri Dish mould (Sigma Ald-
rich) and transferred to 12-well plates (Corning)
as previously described [31]. hPSC-derived somatic
cells were incubated with 1 ml/10 cm2 of TrypLE
express (ThermoFisher) for 5–20 min at 37 ◦C,
dependent on the cell type. Following this, the reac-
tion was stopped by adding the same volume of
liver sphere medium supplemented with 10 µM
Y-27632 (Biotech). After detaching, hPSC-derived
hepatic progenitor cells and hepatic stellate-like cells
were filtered to get a single cell suspension using a
30 µm cell strainer (Sarstedt) and then centrifugated
at 1500 rpm for 10 min. Liver sphere medium con-
sisted of a 1:1 mixture of William’s E media and
SFM-Endothelial media with 5% Serum replacement
(ThermoFisher), 1% Glutamax and 1% penicillin-
streptomycin (ThermoFisher). The cell pellet was
resuspended in liver sphere medium, supplemented
with 10 µM Y-27632 (Biotech), 10 ng ml−1 EGF
(Biotech), 10 ng ml−1 FGF (Peptrotech), 10 ng ml−1
HGF (Peprotech), 20 ng ml−1 OSM (Peprotech) and
50 ngml−1 VEGF (Biotech) at a density of 7,68× 106
live cells ml−1 for hepatic progenitor cells and 7.68×
105 live cells ml−1 for hepatic stellate-like cells. Post-
detachment, hPSC-derived endothelial-like cells were
magnetic-associated cell sorting (MACS) enriched
using CD144 MicroBeads (Myltenyi Biotec) and
resuspended in growth factor and Y-27632 sup-
plemented liver sphere medium at a density of
5.12 × 106 live cells ml−1. The agarose micro-
plates were seeded by transferring 190 µl of a solu-
tion containing the different cell types at the ratio
of 10:3:1 (hepatic progenitor:endothelial cell:stellate
cell). After 2–3 h, 1.5 ml of growth factor supple-
mented liver sphere medium was gently added to
each well of 12-well plate. Media was replaced every
48 h.
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2.1.6. Automated production of liver spheres
Following hPSC differentiation and cell detachment
and endothelial enrichment, a cell mixture contain-
ing 1 volume of hepatic progenitor cells solution at
10.95× 106 live cells ml−1, 0.5 volume of endothelial-
like cells solution at 7.3 × 106 live cells ml−1 and 0.5
volume of HSCs at 2.19× 106 live cells ml−1 (or same
volume of media in the absence of a cell type) was
prepared to a final cell ratio of 10:3:1 (HB:ELC:HSC).
The multidrop system (ThermoFisher 5840300) was
employed to dispense the cell solution into a ‘V’ shape
96 well plate. A Viaflo 96 head pipette system (Integra
6001) was employed to seed 40 µl of cell containing
solution to each well of a 96 well-hydrogel array con-
taining 73 microwells of 500 µm, per well (Gri3D,
Sunbiosciences). Once liver spheres were aggregated,
200 µl of liver sphere medium was added into the
feeding chamber with using the Viaflo 96 head pipet-
ting system (Integra 6132). Media changes were per-
formed every 48 h using both the multidrop and
Viaflo.
2.1.7. Cancer cell co-culture assay
Hepato-endothelial (HE) liver spheres 4 weeks post-
aggregation were used for co-culture assays with can-
cer cell lines. Single cell suspensions of MIAPaCa-2
(a pancreatic ductal adenocarcinoma cell line) and
PDAC (Pancreatic ductal adenocarcinoma cell line)-
A (Mouse KPC PDAC cell line) were labelled with
CellTracker Red dye (ThermoFisher, C34552) as per
manufacturer’s instructions prior to plating 5 × 104
cells into polyHEMA-coated 96-well plates contain-
ing HE liver spheres in liver sphere medium. After
24 h, samples were fixed, stained with Alexa Fluor-
488 Phalloidin, and embedded in 1% agarose.Z-stack
tile scans of each well were imaged with an Opera
PhenixTM High-Content Screening system and inter-
actions between cancer cells and liver spheres scored
in ImageJ. PANC1 cells were purchased from ATCC
(American Type Culture Collection) and PDAC-A
cells were derived from mice with tumours express-
ing KRas G12D and P53 R172H gifted from Dr S Karim
and Dr J Morton at the Beatson Institute.
2.2. Phenotypic and functional characterisation
2.2.1. Immunofluorescence
Liver spheres were fixed for at least 1 h in 4% neut-
ral buffered formalin solution (pH 7.4) at 4 ◦C
and washed twice with PBS at room temperature
before embedding in agarose. Agarose-embedded
liver spheres were then embedded in paraffin and
sectioned at 4 µm. Antigen retrieval was performed
by heating dewaxed and rehydrated sections in 1×
Tris–EDTA buffer solution for 7 min in microwave.
Washed slides were used for subsequent staining. To
stain sectioned spheres, stem cell derived tissue was
blocked with 10% BSA in PBS-tween and incub-
ated with primary antibody overnight at 4 ◦C. The
primary antibody was detected using species-specific
fluorescent-conjugated secondary antibody. Sections
were counterstained with NucBlue Hoechst 33342
(Sigma-Aldrich) and mounted with Fluoromount-
G (SouthernBiotech) before microscopy. Images
were taken using a Nikon Eclipse e600 microscope
equipped with a Retiga 2000 R camera (Q-Imaging)
and Image-Pro Premier software. Antibodies used are
listed in supplementary table 1
For whole mount staining liver spheres were fixed
using 4% PFA for 30 min. Following fixation, cells
were washed three times with 1× PBS. Liver spheres
were stained with Bodipy 493/503 (1:2000) and
NucBlue Live ReadyProbes® Reagent (1 drop ml−1)
and incubated 4 h at RT in the dark. Following
staining, three 1× PBS washes were performed and
liver spheres were transferred into an ibidi µ-Slide 8
Well chamber and resuspended into a 60% (vol/vol)
glycerol and 2.5 M fructose clearing solution [32].
Images were taking with the Confocal microscope
Nikon A1-R HD25 using a Plan Apo λ 20× objective,
Nikon A1 LFOV camera and 0.95 µm Z-step.
2D cell cultures were fixed in 100% ice-coldmeth-
anol at −20 ◦C for 30 min. Following this, cells
were washed twice with 1× PBS at room temperat-
ure. Cell monolayers were blocked with PBS-0.1%
Tween containing 10%BSA for 1 h, and themonolay-
ers were incubated with primary antibodies diluted
in PBS-0.1% Tween/1% BSA at 4 ◦C overnight. The
following day, the primary antibody was removed,
and the fixed monolayers were washed three times
with 1× PBS-0.1% Tween/1% BSA. Following this,
the cells were incubated with the appropriate sec-
ondary antibody diluted in PBS/0.1% Tween/1% BSA
for 1 h at room temperature and washed three times
with 1× PBS. Cultures were then mounted with Per-
maFluor aqueous mounting medium (Thermo Sci-
entific) and counterstained with NucBlue Hoechst
33342 (Sigma-Aldrich). The cells were imaged with
an Axio Observer Z1 microscope with LD PlanNeo-
Fluar objective lenses (Carl Zeiss). This microscope
was coupled to a Zeiss AxioCamMR3 camera used
for image acquisition. The images were processed
through Zeiss Axiovision SE 64 Rel 4.8, with Zeiss
Axiovision version 4.9.1.0 used to analyse the images.
The percentage of positive cells and SDwas calculated
from eight fields of view.
2.2.2. High content imaging and analysis
Image acquisition was performed using the auto-
mated Operetta fluorescent microscope. In brief,
plates were placed in the Operetta and a single image
at 2× was acquired to image most of the well sur-
face. Sphere segmentation for image analysis was per-
formed using the Columbus image analysis software.
Texture-based pixel classification was employed for
background removal by selecting multiple examples
of selected pixels and background pixels. Next,
an inverted image was used for sphere identific-
ation based on sphere size and texture. Finally, a
4
Biofabrication 13 (2021) 015009 B Lucendo-Villarin et al
quality control step using object classification was
employed for sphere selection. This was performed
so that properly segmented spheres were analysed.
Finally, object count and morphology quantification
were employed for sphere count and area
quantification.
2.2.3. Flow cytometry
Single-cell populations were resuspended in FACS
(Fluoresecent Activated Cell Sorting)-PBS (PBS con-
taining 0.1% BSA and 0.1% sodium azide). The cells
were counted and diluted to a density of 1× 106 viable
cells ml−1. A total of 2× 105 cells were incubated for
30 min at 4 ◦C with conjugated antibodies to CD144
(BD Biosciences, 1:40 dilution), CD31 (eBiosciences,
1:100 dilution), CD166 (BD Biosciences, 1:100 dilu-
tion) or CD140b (BD Biosciences, 1:40 dilution).
Cells were washed twice in FACS-PBS. Cells incub-
ated with isotype controls were included as control
and dead cells and debris were excluded from the ana-
lysis based on scatter characteristics. Data for at least
10 000 live events were acquired for each sample using
a BD LSR Fortessa cytometer and were analysed using
FlowJo version V10 software (FlowJo LLC). Data are
presented as percentage positive staining.
2.2.4. Protein secretion
To measure alpha-fetoprotein and albumin secre-
tion, liver spheres were maintained in supplemen-
ted liver sphere medium without SFM-Endothelial
media and in the presence of 10 µM hydrocortisone
21-hemisuccinate sodium salt. Culture media was
collected after 24 h and quantified using commer-
cially available ELISA kits (Alpha Diagnostic Interna-
tional). Data were normalised by total protein con-
tent measured using bicinchoninic acid (BCA) assay
(ThermoFisher). Protein secretion in 2D hepatocyte
like cells (HLCs) cultureswas performed as previously
described [28].
2.2.5. Cytochrome P450 activity
To measure Cyp3A and Cyp1A2 activity, 50 µM of
Luciferin-PFBE substrate (Promega) or 100 µM of
Luciferin-ME (Promega) were incubated with liver
spheres maintained in liver sphere medium. Cyto-
chrome P450 activity was measured 24 h later using
the P450-Glo assay kit (Promega) according to man-
ufacturer’s instructions. Cytochrome P450 activity
in 2D HLCs cultures was performed as previously
described [28].
2.2.6. Exposure to signalling pathway inhibitors
The selective small molecule inhibitors for the c-Met
receptor (Mesylate), the VEGF receptor 1, 2 and 3
(axitibin), for the VEGF receptor 2 (DMH4) and
the glycoprotein (gp) 130 receptor (Sc144) were all
purchased from Tocris. They were resuspended in
dimethyl sulphoxide, DMSO (Sigma Aldrich) and
diluted 1:1000 in liver spheroid medium according
to the manufacturers recommended IC50 concentra-
tions. Melysate was employed at 7 nM, axitibin was
employed at 0.2 and 1.2 nM, DMH4 was employed at
161 nM and SC144 was employed at 720 nM. Inhibit-
ors and the controls were added to liver sphere cul-
tures for the denoted time points. Fresh inhibitors
and medium were added every 48 h.
2.2.7. Assessment of cytochrome P450 metabolism
To assess metabolic activity, stem cell derived liver
spheres were incubated with compounds that are
metabolised by specific cytochrome P450 enzymes.
BMS-872397-01 was selective for Cyp2C19, BMS-
808565-01 and BMS-809506-01 were selective for
Cyp2C9, BMS-827278-01 and BMS-835981-01 were
selective for Cyp2D6 and BMS-707756 was select-
ive for Cyp3A4. BMS (Bristol Myers Squibb) com-
pounds were diluted in dimethyl sulphoxide, DMSO
(Sigma Aldrich) to obtain a 1000× stock concentra-
tion (50 mM) and were subsequently diluted 1:1000
in supplemented liver spheroid medium and applied
to the cells for 72 h at 37 ◦C in 5% CO2. Cell viabil-
ity was measured using RealTime-Glo MT Cell Viab-
ility Assay (Promega) following the manufacturer’s
instructions, at 72 h post exposure. Results were nor-
malised by protein contentmeasured using BCA assay
(ThermoFisher) and compared to cell viability in the
presence of the vehicle control.
2.2.8. Cell viability in response to healthy and diseased
blood plasma
To assess the response of the stem cell derived liver
spheres to a clinically relevant situation, spheres
exposed to 20% of human plasma serum isolated
from patients with paracetamol overdose, for 48 h.
Cell viability was measured using RealTime-Glo MT
Cell Viability Assay (Promega) following the manu-
facturer’s instructions and determined at 48 h post
exposure. Results were normalised by total protein
content measured using BCA assay (ThermoFisher)
and compared to cell viability in the presence of 20%
healthy human serum (Sigma Aldrich).
2.2.9. Liver sphere paracetamol exposure
Paracetamol (Sigma-Aldrich) was prepared as a 4 M
stock in DMSO and diluted in liver spheroid medium
to 10 mM. At day 17, liver spheres were exposed to
paracetamol (10 mM) for 48 h in the incubator at
37 ◦C. Cell viability was measured using RealTime-
Glo MT Cell Viability Assay (Promega) following
the manufacturer’s instructions and determined after
48 h post exposure.
2.2.10. Oil Red O staining and quantification
The oil red O (ORO) stock solution was prepared
by diluting 0.5 g of ORO in 100 ml isopropanol and
filtered.OROworking solutionwas prepared by dilut-
ing 30 ml of stock solution with 20 ml of distilled
water. Following lactate, pyruvate and octanoate
5
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(LPO) treatment, sphereswere fixed using 4%PFA for
30min. Following fixation, three 1× PBSwashes were
performed. Following this, liver spheres were washed
with 60% isopropanol followed by incubation in the
ORO working solution for 15 min at RT, with regu-
lar shaking. After staining, multiple washes with 60%
isopropanol were performed until clear. Next, liver
spheres were transferred into a 1.5 ml tube and 150 µl
of isopropanol transferred into the tube to elute the
ORO from the spheroids (30 min with shaking at
RT). Each sample was centrifuged at 10 000 rpm for
5 min and 50 µl of the solution were transferred (in
triplicate) into a clear 96-well plate and measured at
an absorbance of 490 nm. Protein quantification was
performed using BCA assay.
2.2.11. LPO treatment
Liver spheres were exposed to sodium l-lactate
(20 mM), sodium pyruvate (2 mM) and octanoic
acid (4 mM) (all Sigma, Gillingham, UK) for 48 h to
induce fat loading as previously described [16].
2.2.12. Cytokine detection
Cytokines were quantified from cell culture super-
natant using a V-PLEX Human CRP Kit and a
U-PLEX Biomarker Group 1 (hu) Assays (Meso Scale
Discovery) following themanufacturer’s instructions.
Twenty five microlitres of liver spheroid supernatant
was used for detection. The plate was read on aQuick-
Plex SQ 120 analyser (Meso Scale Discovery).
2.2.13. Ethics
Ethical approval was from Scotland A Research and
Ethics committee. Patients or their nominated next
of kin provided informed consent to blood sampling
and analysis. Peripheral blood samples were obtained
on the day of admission to the Scottish Liver Trans-
plant Unit. Serum was collected after centrifugation
and stored at −80 ◦C until thawing for the experi-
ments. The patient’s clinical measurements are sum-
marised in supplementary table 1.
3. Results
3.1. Generation of pure populations of stem cell
derived hepatic progenitors and endothelial cells
for tissue engineering
Stem cell derived hepatic progenitor cells were pro-
duced using a well-defined differentiation pro-
cess (figure 1(A) [28]). Stem cell morphology
progressively changed throughout the differen-
tiation process, culminating in the acquisition
of cobblestone morphology (figure 1(B)). Stem
cell derived hepatic progenitor populations were
homogeneous with cells expressing cytokeratin 19
(99%± 0.8), HNF4α (98%± 1.7), alpha-fetoprotein
(92.8%± 1.2) and albumin (39%± 4.1) (figure 1(C))
and demonstrated the capacity to form functional
HLCs (supplementary figure 1 (available online at
https://stacks.iop.org/BF/13/015009/mmedia)).
Stem cell derived endothelial like cells (ELCs)
were produced using a modified version of an
established procedure (figure 1(D) [29],). Again,
we observed significant changes in cell morphology
as pluripotent cell differentiation proceeded (fig-
ure 1(E)). ELC populations were not as homogen-
eous, ranging from 41% to 64% purity (supple-
mentary figure 2). Therefore, MACS enrichment for
CD144 was employed, resulting in a homogeneous
population of endothelial cells positive for CD144
and CD31 (on average 95.3% ± 3.6) (figure 1(F)).
Following basic characterisation, hepatic progenitor
cells in combination with ELCs were aggregated
(3:1 ratio) using agarose multi-well technology (fig-
ure 1(G)) allowing the production of homogeneous
liver spheres (HE) with an average size of 288 µm,
(±20.04 µm) (figure 1(H)).
3.2. Characterisation of stem cell derived liver
sphere structure and function
Following formation, HE liver sphere structure
and function were studied. To understand sphere
structure, liver spheres were fixed 2 weeks post-
aggregation, embedded and sections cut for immun-
ostaining. We employed the hepatocyte markers,
E-Cadherin and HNF4α, and the endothelial mark-
ers, VE-Cadherin and CD31, to investigate multi-
cellular organisation and interaction between hep-
atocytes and endothelial cells (figure 2(A)). Within
the sphere, hepatocytes were positioned in the outer
layer, surrounding endothelial tubular structures. In
addition to endothelial markers, mesenchymal status
was confirmed by vimentin localisation with CD31
(figure 2(A)). To gain insight on sphere architec-
ture, whole mount staining was performed to assess
hepatocyte and endothelial structure by staining for
HNF4α and CD31. Whole sphere imaging revealed
CD31 positive endothelial tubes radiated from the
centre of the sphere toward the outer layers (supple-
mentary movie 1).
In addition to protein expression, we also stud-
ied cytochrome P450 1A2 and 3A metabolism at dif-
ferent time points. Cyp1A2 activity increased during
time, from 101416 ± 126986 RLU ml−1 mg−1 pro-
tein (week 1) to 1.63× 106± 610596 RLUml−1mg−1
protein (week 4). Cyp3A activity also increased dur-
ing this period of time, from 15010 ± 6147 RLU
ml−1 mg−1 protein (week 1) to 578958 ± 311661
RLU ml−1 mg−1 protein (week 4) (figure 2(B)).
We successfully obtained hepatic progenitor cells
(supplementary figure 1) and ELCs (supplement-
ary figure 2) and formed HE liver spheres from two
other pluripotent stem cell lines. Both H9 andMan12
derived liver spheres displayed Cyp 1A2 and 3A
activity (supplementary figure 3). The secretion of
two liver proteins, albumin and alpha-fetoprotein,
was also studied. At week 1 liver spheres secreted
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Figure 1. Pluripotent stem cell differentiation and liver sphere formation. (A) Schematic representation of the protocol used to
differentiate hPSCs to hepatic progenitor cells. (B) Phase contrast images of representative fields of view of hPSC at the start of the
differentiation (left) and at the hepatic progenitor stage (right). Images of hPSC were taken at×4 magnification and the scale bar
is 200 µm. Images of endothelial like cells were taken at×10 magnification and the scale bar is 100 µm (C) Hepatic progenitor
cell immunostaining for AFP, albumin, cytokeratin 19 and HNF4α on hepatic progenitor cells. IgG antibodies were used to
demonstrate staining specificity. For each marker, five random fields of view containing at least 400 cells were counted. Images
were taken at×20 magnification and the scale bar represents 100 µm. (D) Schematic representation of the protocol used to
differentiate hPSCs to early endothelial cells. (E) Phase contrast images of representative fields of view of hPSC at the start of the
differentiation (left) and at the endothelial stage (right). Images of hPSC were taken at×4 magnification and the scale bar is
200 µm. Images of endothelial like cells were taken at×10 magnification and the scale bar is 100 µm (F) Representative result
following MACS-mediated enrichment for CD144 expressing cells analysed by flow cytometry (mean± SD, n= 4). (G) Phase
contrast images of representative fields of view of agarose microwells containing liver spheres 24 h post-aggregation. Images were
taken at×4 magnification and the scale bar represents 400 µm. (H) Size distribution of liver spheres (mean± SD, n= 100).
Abbreviations: HNF4α-Hepatocyte Nuclear Factor 4α, AFP-alpha-fetoprotein, CK19. Cytokeratin 19, ALB-Albumin,
IgG-Immunoglobulin G.
3149 ± 746 ng ml−1 mg−1 protein of albumin
and the production did not significantly change by
week 4 (2983 ± 1472 ng ml−1 mg−1 of protein).
Alpha-fetoprotein secretion displayed a similar trend
with no statistically significant variations between
week 1 (5858± 974 ngml−1 mg−1 protein) and week
7
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Figure 2. Liver sphere phenotypic characterisation. (A) Immunofluorescent images of liver spheres staining E-Cadherin and
HNF4α (hepatocytes) and CD31, VE-Cadherin and Vimentin (endothelial cells). IgG antibodies were used throughout to
demonstrate staining specificity. Images were taken at×20 magnification and the scale bar is 120 µm. (B) Cytochrome P450 1A2
and 3A activity were analysed at different time points during liver sphere culture (mean± SD, n= 6). (C) Secretion of the serum
proteins albumin and alpha-fetoprotein were measured by ELISA at the denoted times (mean± SD, n= 6). (D) ATP depletion in
liver spheres exposed to compounds metabolised by specific cytochrome P450 enzymes to toxic endpoints. Data was compared to
vehicle control and analysed using the one-way analysis of variance (ANOVA) and Dunnett’s multiple comparison test (α= 0.05)
(mean± SD, n= 6). Abbreviations: HNF4α-Hepatocyte Nuclear Factor 4α, E-Cadh-E-Cadherin, VE-Cadh-Vascular endothelial
cadherin, Vim-Vimentin, IgG-Immunoglobulin G.
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4 (7318± 3715 ngml−1 mg−1 protein) (figure 2(C)).
Longer term culture of HE liver spheres resulted in a
decreased secretion of alpha-fetoprotein.Week 7 liver
spheres secreted 427 ± 146 ng ml−1 mg−1, this was
reduced to 175 ± 54 ng ml−1 mg−1 protein at week
10. By week 14 alpha-fetoprotein secretion decreased
to 53 ± 34 ng ml−1 mg−1 protein (supplementary
figure 4). Further metabolic characterisation was per-
formed employing a set of training compoundswhich
assess adult Cyp P450 drug metabolising activity.
The compounds used, are metabolised by the specific
cytochrome P450 enzyme to toxic endpoints, redu-
cing cell viability. Therefore, Cyp P450 activity can
be inferred by decreased ATP production. Incubation
of liver spheres with those these compounds for 72
h resulted in sphere destruction and significant ATP
depletion, ranging from 41% to 90%, dependent on
the substrate used (figure 2(D)).
3.3. Liver sphere exposure to high energy
substrates, paracetamol, blood plasma and cancer
cell aggregates
After liver sphere characterisation, their ability to
model disease was tested. Firstly, the ability of liver
spheres to store fat was examined following exposure
to high energy substrates [16]. Following 48 h LPO
exposure, we incubated liver spheres with BODIPY
to stain for lipid droplets. We observed an increase
in the BODIPY staining in liver spheres exposed to
LPO (figure 3(A)). Lipid accumulation was further
supported and quantified by Oil red O staining. We
observed a 3.4-fold increase in lipid staining com-
pared to the vehicle control (figure 3(B)) .
Following fat loading, we wished to study DILI.
For these studies, we used, a common analgesic
which can cause severe liver damage when taken
above the recommended dose. Exposure to 10 mM
of paracetamol resulted in approximately 50% reduc-
tion in the ATP levels (figure 3(C)) which is in line
with the primary human hepatocytes [33]. To fur-
ther investigate the ability of the spheres to sustain
liver function following DILI, we exposed the liver
spheroids to plasma isolated from patients following
paracetamol overdose. After 48 h exposure we meas-
ured cell viability. We detected significant ATP deple-
tion following exposure to patient sera compared to
a heathy control. However, liver sphere structure was
maintained following exposure, suggesting that this
model could be used to study liver damage and regen-
eration in future experiments (figure 3(D), supple-
mentary table 1).
The liver is a common site of metastasis for
many cancers, including pancreatic and colon can-
cer, and liver metastases are associated with poor
patient prognosis [34, 35]. 3D culture systems have
the potential to recapitulate in vivo cancer cell–liver
niche interactions in a controlled environment and
are amenable to mechanistic studies. To investigate
the potential of liver spheres as a model of liver meta-
stasis, single cell suspensions of two pancreatic ductal
adenocarcinoma cell lines (MIAPaCa-2 and PDAC-
A) were co-cultured with liver spheres for 24 h, prior
to fixation and whole-mount imaging. Both cancer
cell lines spontaneously formed spheroids in sus-
pension, but also interacted with HE liver spheres
(figure 3(E)). Interactions often involved a close,
flattened surface between two spheres (termed
‘Touching’) but also instances where cancer cells
disrupted the boundary of liver spheres (termed
‘Invading’) (figure 3(E), right panels). Blind scor-
ing of these interactions revealed that roughly 50% of
HE spheres interacted with cancer cells, and sugges-
ted the PDAC-A cells were more invasive (Invading;
PDAC-A: 13.3%, MIAPaCa-2: 4.5%), in agreement
with this cell line’s high liver metastatic potential
[36] (figure 3(F)). Thus, HE liver spheres show dif-
ferential interactions with cancer cell lines support-
ing their potential use as a model of the metastatic
niche.
3.4. Automated production of human liver spheres
Blood vessel remodelling and stability in the liver
requires the presence of the pericyte [37]. Therefore,
in order to improve model physiology we introduced
hepatic stellate cells (HSCs), differentiated from
pluripotent stem cells [38] (supplementary figure
5(A)). In vitro derived HSCs displayed mesenchymal
morphology (supplementary figure 5(B)) and were
homogenous, expressing the HSC markers, platelet-
derived growth factor (PDGF) Rβ (98.1%± 2.1) and
ALCAM (97.2%± 1.6) (supplementary figure 5(C)).
To improve technology scale-up and reduce vari-
ation, we transferred our manual aggregation sys-
tem to an automated platform (figure 4(A)). Fol-
lowing differentiation and quality control, the liquid
handling dispenser was used to prepare the cell
combination. Following this, an automatic pipet-
ting system was employed to dispense cells into
microwell plates for self-aggregation. This system
was also used for sphere maintenance and for
downstream applications. Plate imaging and sphere
quantification was carried out 48 h post-seeding
using an Operetta high-content imaging system
(figures 4(B) and (C)). Analysis was performed
using Columbus software and revealed consistency
in sphere number per well between columns, with
a median of 70 segmented spheres per well (fig-
ure 4(D), supplementary figure 6). Cell function
was measured analysing cytochrome P450 1A2 activ-
ity in HE and hepato-endothelial-stellate (HES)
liver spheres. Cyp 1A2 activity increased with time
in culture and was significantly higher by week
4 (figure 4(E)). Notably automated manufacture
reduced the standard deviation by>2-foldwhen com-
pared to agarose microwell experiments (figures 2
vs. 4).
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Figure 3. Liver spheres model clinically relevant situations. (A) Immunofluorescence images of liver spheres staining positive
for fat droplets (Green-bodipy stain) following exposure to lactate, pyruvate and octanoate (LPO) treatment. (B) Oil red O
quantification of liver spheres fat loading after LPO treatment. Data was compared to liver spheres exposed to vehicle control and
analysed using unparied t-test (mean± SD, n= 4). (C) Liver sphere ability to metabolise paracetamol to toxic by-products was
examined and cell viability measured by ATP synthesis. Data was compared to liver spheres exposed to vehicle control and
analysed using unpaired t-test (mean± SD, n= 7) (D) Exposure to fulminant liver plasma, isolated from patients hospitalised
from paracetamol overdose, was assessed measuring ATP synthesis. Data was compared to hepatospheres exposed to healthy
control serum. Analysis was performed using with a one-way analysis of variance (ANOVA) (α= 0.05) and Dunnett’s multiple
comparison test (mean± SD, n= 4). (E) Liver sphere interaction with two pancreatic cancer cell lines (MIAPaCa-2 and
PDAC-A). Representative maximum intensity projections of liver spheres cultured with pancreatic cancer cells. Right panels show
different types of interactions observed. (F) Scoring of interactions of MIAPaCa-2 and PDAC-A cells with HE spheres.
Abbreviations: APAP-paracetamol.
3.5. Liver sphere screening to determine essential
signalling requirements for tissue self-assembly,
function andmaintenance in vitro
To study the signalling requirements for tissue self-
assembly, function andmaintenance, we performed a
screen. Inhibitors that modulated signalling pathways
important to liver development and regeneration
were employed (figure 5 and supplementary figure 7).
For this purpose, hepatospheres (H), HE and HES
liver spheres were self-aggregated in the presence of
the specific inhibitors for 2 and 4 weeks, with cell cul-
ture medium replenished every 2 d. At the end of the
experiments, we used high-content analysis (supple-
mentary figure 6) to segment and calculate the size
and number of spheres. Cyp P450 metabolic activity
was assessed as before (figure 5 and supplementary
figure 7).
Reduced c-Met signalling did not change the
number of H, HE or HES liver spheres formed
(figure 5(A), supplementary figure 7(A)). However,
sphere size was significantly reduced when the c-Met
receptor was inhibited in H, HE and HES spheres
at 2 weeks post-treatment, but not 4 weeks (fig-
ure 5(B), supplementary figure 7(B)). In response
to gp130 receptor inhibition, we did not observe a
reduction H, HE or HES sphere number (figure 5(A),
supplementary figure 7(A)). However, liver sphere
size was reduced in HES liver spheres at 2 weeks and
in all spheres after 4 weeks (figure 5(B), supplement-
ary figure 7(B)). In response to VEGFR inhibition,
H sphere numbers were reduced after treatment with
the VEGFR 1–3 inhibitor for 4 weeks (supplementary
figure 7(A)). HE and HES, but not H sphere size were
increased in response to VEGFR-2 inhibition at the
4 week time point (supplementary figure 7(B)).
Following this, we examined sphere meta-
bolic function following inhibitor exposure. In
H spheres treated with the c-Met inhibitor for
2 weeks, we observed a reduction in Cyp3A
activity. Whereas, HE sphere Cyp1A2 and 3A
activity increased (figures 5(C) and (D)). After
4 weeks treatment, only HE sphere Cyp1A2 activity
remained improved (supplementary figures 7(C) and
(D)). In response to gp130 inhibition, both Cyp1A2
and Cyp3A activity was reduced in H spheres. In
HE spheres. Cyp3A activity was reduced at 2 weeks
onwards (figure 5(D)), with Cyp 1A2 affected at
week 4. In HES spheres, cytochrome P450 activity
was not significantly affected, but appeared close
to baseline following gp130 inhibition for 4 weeks
10
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Figure 4. Automated production of human stem cell derived liver spheres. (A) Schematic representation of the production
pipeline. hPSCs are differentiated into hepatic progenitors, endothelial cells and HSCs and mixed at the specified ratio (10:3:1).
Next, the cell suspension containing the three cell types is dispensed into a 96-well V shape plate using the multidrop automatic
liquid handling system. Finally the cells are pipetted into the microwells using the Viaflo automatic pipette. (B) Plate overview of a
96 well-plate liver spheres. Scale bar represents 10 mm (C) Well overview with liver spheres in a microwells within a 96-well plate.
Scale bar represents 500 µm (D) Number of liver spheres across the plate. (mean± SD, n= 8) (E) Cytochrome P450 1A2 activity
from liver spheres produced by the automated pipeline analysed at different time points (mean± SD, n= 7). Abbreviations:
HB-Hepatic progenitor cell, EC-Endothelial cell, HSC-Hepatic stellate cells, HE-hepato-endothelial liver sphere,
HES-hepato-endothelial-stellate liver sphere.
(supplementary figures 7(C) and (D)). In H spheres
treated for 2 weeks with the VEGFR-2 inhibitor, we
observed decreased in Cyp3A activity (figure 5(D)).
However, no effects were observed at the 4 weeks
time point (supplementary figures 7(C) and (D)).
In H and HE spheres treated with the VEGFR-2 and
-3 inhibitors for 2 weeks, we observed an increase
in Cyp1A2 activity, and a decrease in Cyp3A activity
(figures 5(C) and (D)). At 4 weeks inhibition, H
spheres displayed decreased Cyp1A2 and 3A activ-
ity with no observed effects in HE or HES spheres
(supplementary figures 7(C) and (D)). In H spheres
treated with VEGF receptors 1–3 inhibitors we
observed decreased in Cyp1A2 and 3A activity from
2 weeks onwards, which was not observed in HE and
HES spheres (figures 5(C) and (D) and supplement-
ary figures 7(C) and (D)).
Following the inhibitor experiments, we were
keen to have a better understanding of the cellular
contribution to liver sphere secretion. In these
experiments, we examined the secretion of eryth-
ropoietin (EPO), the inflammatory cytokine
interleukin-13 (IL-13) and the acute phase protein
C-reactive protein (CRP) [30, 39]. We employed H
andHES spheres for these experiments to look for dif-
ferences in cell biology following exposure to a high
energy ‘diet’ (LPO—figure 3) and TGF (Transform-
ing growth factor)-beta, a driver of fibrosis [30]. H
spheres secreted approximately 3-fold less EPO than
HES spheres, indicating that endothelial and stel-
late cell contribution to EPO production [40, 41]. In
response to both disease-mimicking environments,
we observed a reduction in EPO secretion indicating
loss of sphere function in HES spheres only. This was
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Figure 5. Determination of cell signalling involved in sphere formation, maintenance and function.Hepato liver spheres (H),
hepato-endothelial liver spheres (HE) and hepato-endothelial-stellate liver spheres (HES) were produced by the automated
pipeline, and incubated with inhibitors targeting key liver signalling pathways. (A) Quantification of the average sphere number
per well following inhibitor exposure (box plot with mean and min-max, n > 6). (B) Quantification of the average sphere area per
well following inhibitor exposure (box plot with mean and min-max, n > 6). (C) Cyp1A2 and (D) Cyp3A activity following
2 weeks inhibitor exposure (mean± SD, n > 4). Data was analysed using two-way analysis of variance (ANOVA) and Tukey’s
multiple comparisons test (α < 0.05).
most profound after exposure to LPO (figure 6(A)).
With regard to the inflammatory chemokine, IL-13,
we observed similar secretion levels between H and
HES spheres when treated with vehicle (figure 6(B)).
However, following TGFβ induction, but not LPO
exposure, we observed an ∼2-fold increase in IL-
13 secretion from only HES spheres (figure 6(B)).
Finally, secretion of the acute phase protein CRP
was studied. CRP secretion was increased in both H
and HES spheres following LPO exposure. In con-
trast, only HES spheres demonstrated a significant
increase in CRP secretion when exposed to TGF-β
(figure 6(C)).
4. Discussion
Pluripotent stem cells represent a renewable source
of human cells for tissue engineering. They are cap-
able of large-scale expansion and differentiation into
all the cell types found in the human body. This
means that in theory PSCs could generate an unlim-
ited amount of human tissue for biomedical applica-
tion. While great progress has been made in the field,
the scale-up andmanufacture of stem cell derived tis-
sue does require significant refinement, before indus-
trial manufacture is possible, at an acceptable cost.
In particular, the development of defined in vitro
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Figure 6. Increase in sphere complexity improves disease modelling in vitro. EPO, IL-13 and CRP secretion were analysed
following LPO or TGF-β 25 ng ml−1 for 48 h in H and HES spheres. (A) HES spheres show an increase in basal EPO secretion
with a significant decrease following both LPO and TGF-β exposure (n= 4). (B) Increased IL-13 induction was detected in HES
spheres following TGF-β treatment only (n= 4). (C) CRP secretion was increased in both H and HES spheres following LPO
treatment but only in HES spheres after TGF-β exposure (n= 3). Samples were analysed using with a one-way analysis of
variance (ANOVA) (α= 0.05) with Tukey’s multiple comparisons test.
engineered cellular niches are essential to delivering
a reliable piece of human tissue for biomedical
application.
Our study focussed on the construction of sup-
portive cell microenvironments whichmimic key ele-
ments of organ anatomy and physiology. Central to
this approach was the development of key cell-to-cell
interactions that are normally found in the liver, with
a focus on endothelial cells and HSCs. The endothe-
lium plays an essential role in human liver biology
during embryonic development, through to organ
homeostasis in the adult. During embryonic devel-
opment, before formation of functional blood ves-
sels, endothelial cells promote the outgrowth of the
hepatic progenitors from the liver bud [42]. Sub-
sequently, the acquisition of the hepatic vasculature
advances throughout embryogenesis [43]. The inter-
play between hepatocytes and endothelial cells has
been studied extensively in vivo [44]. Following par-
tial hepatectomy, hepatocytes begin to secrete VEGF,
driven by hypoxia inducible factor 1. VEGF signals
through liver sinusoidal endothelial cell receptors and
stimulates cell proliferation, angiogenesis and secre-
tion of liver mitogens including, hepatocyte growth
factor HGF and IL-6. HGF pathway activation is
mediated by the c-Met receptor, promoting hep-
atocyte proliferation [45]. IL-6 binds with the IL-6
receptor which subsequently forms a complex with
glycoprotein 130 (gp 130), driving signal transduc-
tion and liver regeneration [46].
In addition to endothelial mesenchyme, the stel-
late cell also plays a vital role in the liver. HSCs reside
in the liver within the space of Disse and are intim-
ately associated with both the hepatocyte and the
endothelial cell. In the healthy liver, HSC store vit-
amin A in lipid droplets [47]. However, following
liver challenge, HSC undergo transformation to a
myofibroblast state, providing the liver with an ability
to respond to injury and heal certain types of dam-
age. During normal wound healing, HSCs decrease
matrix secretion and immunomodulation resulting
in scar tissue resolution [47] [48]. In the context
of sustained liver damage multiple proinflammatory
cytokines, such as IL-6, IL-1b, tumour necrosis factor
alpha (TNF-α) as well as Damage-associatedmolecu-
lar patterns are continually released, resulting in the
chronic activation of HSCs and macrophages. This
results in the prolonged secretion of pro-fibrotic sig-
nals, such as TGF-β, PDGF or angiotensin II, leading
to a build-up of scar tissue which is difficult to resolve
[49, 50].
Therefore, in order to build human liver tis-
sue from pluripotent stem cells, we opted to use
endothelial cell and HSC mesenchyme in our system.
Stem cell derived somatic cells were produced under
defined conditions (figures 1–2 and supplementary
figure 5) [29–31]. The combination of stem cell
derived hepatic progenitors, endothelial cells and stel-
late cells from the same genetic background allowed
the generation of functional liver spheres (figures
2–5 and supplementary figures 2 and 7). Import-
antly, liver spheres were capable of modelling com-
plex aspects of liver biology including human drug
metabolism and drug overdose (figures 2–3). Addi-
tionally, liver spheres were able to model increases
in lipid storage, when exposed to high-energy ‘diet’
and therefore may serve as a good model for studying
human fatty liver disease in the future (figure 3). We
also provide evidence that pancreatic cancer cell lines
spontaneously interacted with liver spheres in ways
that recapitulate their innate metastatic potential in
vivo (figure 3). Although patient-derived organoids
of liver metastases have been demonstrated they do
not capture the early stages of metastatic seeding and
13
Biofabrication 13 (2021) 015009 B Lucendo-Villarin et al
growth [51]. Our system presented here is a prom-
ising candidate to capture those early events.
Finally, we automated the production of liver
spheres (figure 4). Stem cell derived liver tissue was
prepared using a combination of engineering pro-
cesses (figure 4). The resulting tissue was functional
and reliable (figure 4) with a >2-fold reduction in
variability when compared to the manual agarose
microwell based system (figures 1 and 2). Given the
reproducibility of the technology, we employed the
automated system to investigate key liver signalling
pathways involved in human liver differentiation
and regeneration, combining biochemical assays and
high content imaging (figure 5 and supplementary
figures 6 and 7). To study the importance of signalling
through c-Met, gp130 and VEGF receptors 1–3 we
employed small molecule inhibitors (figure 5 and
supplementary figure 7).
The inhibition of c-Met signalling for 2 weeks
resulted in spheroid size reduction, likely due to
reduced cell proliferation [52, 53]. The reduction in
sphere size which was associated with significantly
decreased Cyp activity in H spheres and increased
Cyp activity in HE liver spheres. The improvement
of HE sphere function, following c-Met inhibition,
is in line with previous studies [54]. The modula-
tion of Cyp P450 activity was not observed in HES
liver spheres, possibly due to c-Met activation by the
HSCs [55].
Following 2 weeks inhibition of gp130, we
observed a similar number of liver spheres formed,
but a decrease in sphere size in HES spheres only.
Whilst the reduction of Cyp P450 activity was
observed in H and HE spheres at this time point
(figure 5 and supplementary figure 7). At 4 weeks
exposure, we observed a similar number of spheres
formed, but a decrease in H, HE and HES sphere size.
Whereas, metabolic activity was only significantly
reduced in H and HE spheres (figure 5 and supple-
mentary figure 7). gp130 signalling has been reported
to be a key driver of liver maturation and regenera-
tion in rodents and its inhibition likely impacted on
liver sphere phenotype [56, 57]. These observations
reflected the importance of both gp130 and c-Met
signalling in liver sphere formation and function [58,
59] (figure 5 and supplementary figure 7). Notably,
we found that the more complex liver spheres were
less affected by c-Met and gp130 signalling inhibi-
tion, likely due to trophic support provided in those
spheres.
We then went onto study the importance of the
VEGF receptor in liver sphere formation and function
(figure 5 and supplementary figure 7). In response
to VEGF receptor inhibition, we did not observe any
changes in sphere number or size following 2 weeks
treatment (figure 5). However, VEGFR-2 inhibition
for 4 weeks resulted in an increase in HE and HES,
but not in H sphere size (supplementary figure 7). In
terms of activity, H spheres demonstrated decreased
Cyp3A activity in response to VEGFR-2 inhibition at
2 weeks only. Whereas inhibition of VEGFR-2 and -3
resulted in increased Cyp1A2 activity and decreased
Cyp3A activity. In response to VEGFR-1–3 inhibi-
tion, we observed reduced Cyp3A and 1A2 activity
from 2 weeks onwards. In HE spheres we observed
less effects of the VEGF inhibitors, with increased
Cyp1A2 activity and reduced Cyp3a activity changes
at 2 weeks post VEGFR-2 and -3 inhibition only.
Whereas, we did not observe metabolic perturbation
in HES spheres following VEGF inhibition.
Following the inhibitor studies, we examined
alterations in liver sphere protein secretion. We
examined EPO production, which suppresses
inflammatory cytokine production [60], versus the
inflammatory cytokine IL-13 and acute phase pro-
tein (CRP) production. Simple (H) and more com-
plex spheres (HES) spheres were exposed to a high
energy ‘diet’ (LPO—figure 3) and TGF-beta, a driver
of fibrosis [30]. We observed 3-fold increased EPO
secretion from HES spheres, indicating endothelial
and stellate cell contribution to EPO production [40,
41]. This was significantly reduced after HES expos-
ure to TGF-β and LPO (figure 6(A)). The reduction
in EPO in HES spheres was consistent with increased
production of the inflammatory cytokine IL-13, fol-
lowing TGF beta induction (figure 6(B)); and CRP
production, following exposure to TGF-β and LPO
(figure 6(C)). The response of H spheres was less
robust, with CRP induction observed following LPO
treatment only (figure 6(C)).
By taking an incremental approach to building
liver spheres, we demonstrate the stabilising influence
of endothelial and stellate cells on liver tissue pheno-
type (figure 5 and supplementary figure 7). In addi-
tion, we demonstrate that more complex liver spheres
(HES) secrete proteins which better capture the dis-
ease environment, thereby improving our ability to
study human biology in vitro (figure 6)
5. Conclusion
In conclusion, we have developed an automated dif-
ferentiation system that permits the self-assembly of
human liver tissue in vitro. Importantly, our system
produces functional and phenotypically stable liver
tissue, that permits the modelling of human liver bio-
logy, disease, cell signalling and protein secretion.
Going forward we believe that this resource may have
an important role to play in supporting failing liver
function in humans.
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